Desmopressin Acetate Injection, Solution
NDC Package 62756-529-26

11-digit billing NDC: 62756052926 · Billing unit: ML · 10 ML per package

Package Information

Desmopressin Acetate injection is contraindicated in patients with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate injection [see Warnings and Precautions (5.4), Adverse Reactions (6), Description (11)].Desmopressin acetate injection is contraindicated in patients with the following conditions due to an increased risk of hyponatremia:·         Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min [see Use in Specific Populations (8.5, 8.6) and Clinical Pharmacology (12.3)].·         Hyponatremia or a history of hyponatremia [see Warnings and Precautions (5.1), Drug Interactions (7.1)], Use in Specific Populations (8.4, 8.5)].·         Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion [see Warnings and Precautions (5.1)].·         Polydipsia [see Warnings and Precautions (5.1)].·         Concomitant use with loop diuretics [see Boxed Warning].·         Concomitant use with systemic or inhaled glucocorticoids [see Boxed Warning].·         During illnesses that can cause fluid or electrolyte imbalance, such as gastroenteritis, salt-wasting nephropathies, or systemic infection [see Boxed Warning].Desmopressin acetate injection is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition:·         Heart failure·         Uncontrolled hypertension . This formulation utilizes a injection, solution delivery system. Marketed by Sun Pharmaceutical Industries, Inc., this product is identified by NDC 62756-529 and is authorized under FDA application ANDA091280.

Identification & Billing

NDC Package Code
62756-529-26
Package Description
1 VIAL, MULTI-DOSE in 1 CARTON / 10 mL in 1 VIAL, MULTI-DOSE
Product Code
11-Digit Billing Format
62756052926
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Units Per Package
10 ML
RxNorm Crosswalk
  • RxCUI: 849501 - desmopressin acetate 4 MCG/ML Injectable Solution
  • RxCUI: 849501 - desmopressin acetate 0.004 MG/ML Injectable Solution

Clinical Specifications

Proprietary Name
Desmopressin Acetate
Non-Proprietary Name
Desmopressin Acetate
Substance Name
Desmopressin Acetate
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
  • Intravenous - Administration within or into a vein or veins.
  • Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
  • Intravenous - Administration within or into a vein or veins.
  • Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Usage Information
Desmopressin acetate injection is contraindicated in patients with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate injection [see Warnings and Precautions (5.4), Adverse Reactions (6), Description (11)].Desmopressin acetate injection is contraindicated in patients with the following conditions due to an increased risk of hyponatremia:·         Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min [see Use in Specific Populations (8.5, 8.6) and Clinical Pharmacology (12.3)].·         Hyponatremia or a history of hyponatremia [see Warnings and Precautions (5.1), Drug Interactions (7.1)], Use in Specific Populations (8.4, 8.5)].·         Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion [see Warnings and Precautions (5.1)].·         Polydipsia [see Warnings and Precautions (5.1)].·         Concomitant use with loop diuretics [see Boxed Warning].·         Concomitant use with systemic or inhaled glucocorticoids [see Boxed Warning].·         During illnesses that can cause fluid or electrolyte imbalance, such as gastroenteritis, salt-wasting nephropathies, or systemic infection [see Boxed Warning].Desmopressin acetate injection is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition:·         Heart failure·         Uncontrolled hypertension 

Regulatory & Marketing

Labeler Name
Sun Pharmaceutical Industries, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA091280
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
02-20-2014
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (62756-529). Click a package code to view its specific billing and regulatory data.

1 VIAL in 1 CARTON / 10 mL in 1 VIAL

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 62756-529-26 identifies a specific commercial package of 1 vial, multi-dose in 1 carton / 10 ml in 1 vial, multi-dose of Desmopressin Acetate, a human prescription drug labeled by Sun Pharmaceutical Industries, Inc.. This injection, solution is formulated for intravenous; subcutaneous use and contains desmopressin acetate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sun Pharmaceutical Industries, Inc. on February 20, 2014. The current certification is valid through December 31, 2026.

How is this Sun Pharmaceutical Industries, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 62756052926. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 10 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
62756-529-26
11-Digit CMS (5-4-2)
62756-0529-26

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.